Holen Sie sich die Stockscreener-App
7.62
1.74%
0.13
Handel nachbörslich:
7.53
-0.09
-1.18%
Schlusskurs vom Vortag:
$7.49
Offen:
$7.6
24-Stunden-Volumen:
20,757
Relative Volume:
0.13
Marktkapitalisierung:
$4.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.00M
KGV:
-0.0266
EPS:
-286.8504
Netto-Cashflow:
$-4.43M
1W Leistung:
+0.51%
1M Leistung:
-14.05%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.4283
$7.97
1-Wochen-Bereich:
$6.95
$9.09
52-Wochen-Spanne:
$6.3829
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Firmenname
Decoy Therapeutics Inc
Sektor
Branche
Telefon
346-772-0346
Adresse
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
7.62 | 3.98M | 0 | -5.00M | -4.43M | -286.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-23 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-04-27 | Eingeleitet | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Aktie (DCOY) Neueste Nachrichten
Decoy Therapeutics partners with Quantori on AI peptide platform - Investing.com India
Equity in earnings of Decoy Therapeutics Inc. – GETTEX:FP11 - TradingView
Decoy Therapeutics partners with Quantori on AI peptide platform By Investing.com - Investing.com Nigeria
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - marketscreener.com
Decoy Therapeutics (DCOY) Partners with Quantori to Enhance Anti - GuruFocus
Decoy Therapeutics enters collaboration with Quantori - TipRanks
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform – NEWSnet Michigan - michigan.newsnetmedia.com
Google Cloud-funded AI aims up to 100-fold faster antiviral peptide design - Stock Titan
Current ratio of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Return on assets % of Decoy Therapeutics Inc. – MUN:FP11 - TradingView
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Market Movers | Winners: RVPH, DCOY, ADTX | Losers: RBOT, OLMA, BNAI - Trefis
Decoy Therapeutics to implement 1-for-12 reverse stock split By Investing.com - Investing.com Canada
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split - Finviz
Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing - TipRanks
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com
SLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics (DCOY) Stock Analysis Report | Financials & Insights - Benzinga España
Decoy Therapeutics shareholders approve reverse stock split and equity plan - Investing.com Nigeria
Decoy Therapeutics shareholders approve reverse stock split and equity plan By Investing.com - Investing.com India
Decoy Therapeutics Shareholders Approve Plan and Reverse Split - TipRanks
DCOY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DCOY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Decoy Therapeutics (DCOY) Stock Price, News & Analysis - MarketBeat
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
Decoy Therapeutics Inc Share Price USD0.0001 - Hargreaves Lansdown
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
DCOYDECOY THERAPEUTICS INC Latest Stock News & Market Updates - Stock Titan
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
What is the current Price Target and Forecast for Decoy Therapeutics Inc (DCOY) - Zacks Investment Research
Finanzdaten der Decoy Therapeutics Inc-Aktie (DCOY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):